Skip to main content
. 2017 Feb 1;8(14):22490–22500. doi: 10.18632/oncotarget.14989

Figure 1. Two variants of FANCD2: namely “FANCD2-V1 (V1)” for the long-known FANCD2 and “FANCD2-V2 (V2)” for the overlooked one.

Figure 1

V2 is relatively highly expressed in benign cells or tissues as compared to V1. (A) FANCD2 gene contains two potential polyadenylation signaling motifs, which result in two proteinic variants: V1 and V2 that have a large common amino terminal (1427 AAs) (green-colored) and a 24 or 44 unique AA at the C-terminal respectively (red/V1 or blue/V2) (Black arrowheads indicate the RT-PCR primers used for detecting V1 or V2 mRNA expression.). (B) RT-PCR shows V1 or V2 relative expressions in malignant or matched non-malignant lung tissues. V2 is relatively high expressed in non-malignant tissues as compared to V1 (t-test, **p < 0.01). (C) RT-PCR shows V1 or V2 relative expressions in malignant or non-malignant human cell lines. V1 expression is relatively higher than V2 in malignant cells or transformed cells (PA-1, U2OS, HCT116, RKO, HT-29, LoVo and 293T) compared to non-malignant cells tested (CRL-1790, 293 and WI38) (t-test, **: p < 0.01). (All bar graphs were plotted from ImageJ quantification of RT-PCR results.)